Imran House, Ph.D. and Junyun Lai Ph.D. are Senior Scientists at the biotech start-up, oNKo-Innate in Melbourne, Australia that focuses on developing immuno-oncology therapies. In this episode, they discussed what they do at oNKo-innate, their career transitions from leaving academics to entering the biotech industry, and how CRISPR is impacting cancer-immunotherapy development. They also discussed overcoming common obstacles faced when developing cytokine therapies and future outlooks on clinical trials using these kinds of therapies.

Reach out and connect with both Imran and Junyun on social media platforms:

Imran House, Ph.D.

LinkedIn

X: @ImranHouse

Junyun Lai, Ph.D.

LinkedIn

X: @JunyunLai